
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
+13
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of and ultimately cure neurological diseases. Our pipeline includes programs for Alzheimers disease, amyotrophic lateral sclerosis (ALS), Parkinsons disease, and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACERTM AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including...
Gene therapy,biotechnology,adeno associated virus,research,parkinson's disease,huntington's disease,vector engineering,sf9,alzheimer's disease,als,amyotrophic lateral sclerosis,friedrich's ataxia,sod-1,tauopathies,gene therapy,neurology,neuropharmacology,and cns
Voyager therapeutics, inc operates in the Biotechnology research industry.
Voyager therapeutics, inc's revenue is 101m - 500m
Voyager therapeutics, inc has 201 - 500 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.